147 related articles for article (PubMed ID: 35152356)
1. Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.
Ushimaru Y; Takahashi T; Nakajima K; Teranishi R; Nishida T; Hirota S; Motoori M; Omori T; Kawabata R; Nishikawa K; Saito T; Yamashita K; Tanaka K; Makino T; Yamamoto K; Kurokawa Y; Eguchi H; Doki Y
Int J Clin Oncol; 2022 May; 27(5):921-929. PubMed ID: 35152356
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
[TBL] [Abstract][Full Text] [Related]
3. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
5. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
6. Assessing prognostic factors of long-term survival after surgery for colorectal gastrointestinal stromal tumours.
Yang S; Maspero M; Holubar SD; Hull TL; Lightner AL; Valente MA; Gorgun E; Kalady MF; Steele SR; Liska D
Colorectal Dis; 2023 Dec; 25(12):2325-2334. PubMed ID: 37876119
[TBL] [Abstract][Full Text] [Related]
7. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
[TBL] [Abstract][Full Text] [Related]
8. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
Keung EZ; Raut CP; Rutkowski P
Ann Surg Oncol; 2020 Oct; 27(10):3659-3671. PubMed ID: 32734368
[TBL] [Abstract][Full Text] [Related]
9. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Qianyi W; Mei X; Rui Z; Yong W; Yutao W; Xiaoding S; Xiaoting W
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1493-1500. PubMed ID: 34319443
[TBL] [Abstract][Full Text] [Related]
10. Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months.
Lei C; Zhao B; Wang Q; Ge L; Wang H
J BUON; 2018; 23(2):460-467. PubMed ID: 29745093
[TBL] [Abstract][Full Text] [Related]
11. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.
Kang S; Ryu MH; Bang YH; Kim HD; Lee HE; Kang YK
Cancer Res Treat; 2022 Oct; 54(4):1167-1174. PubMed ID: 34883555
[TBL] [Abstract][Full Text] [Related]
13. Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
Nishida T; Sato S; Ozaka M; Nakahara Y; Komatsu Y; Kondo M; Cho H; Hirota S; Kagimura T; Kurokawa Y; Kitagawa Y;
Gastric Cancer; 2022 Sep; 25(5):956-965. PubMed ID: 35672526
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
16. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
[TBL] [Abstract][Full Text] [Related]
17. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
Liu R; Wu Y; Gong J; Zhao R; Li L; Wan Q; Lian N; Shen X; Xia L; Shen Y; Xiao H; Wu X; Chen Y; Cen Y; Xu X
Cancer Med; 2022 Aug; 11(16):3093-3105. PubMed ID: 35297216
[TBL] [Abstract][Full Text] [Related]
18. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
20. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
